Introduction .
An additional 40% of patients experienced tumour stabilisation for a median of 5 months .
The dose-limiting toxic  effects were severe diarrhoea and neutropenia .
Methods .
Endpoints .
Patients' selection .
Randomisation and study treatments .
Registration forms were sent to Rhone-Poulenc Rorer Research and Development (Antony ,  France) where eligibility criteria  were electronically checked .
Analysis of best supportive care .
Follow-up .
Beyond 1 year ,  only date of death  was traced .
Quality of life .
Statistical analysis .
The randomisation was stratified by centre .
Results .
Patients' data .
The patients' characteristics are shown in table 1 .
Overall survival .
In the supportive-care group there were 71 (79%) events ,  the median duration of which was  6.5 (range 0.7-19.3) months .
Median follow-up was 12.9 months .
In the  supportive-care-alone group there were 53 (77%) events ,   median duration 7.4 (0.7-19.3) months .
In the supportive-care group there were 18 (86%) events ,  the median duration of  which was 3.5 (range 1.1-11.0) months .
Secondary endpoints .
In  the supportive-care group there were 26 (79%) events ,   median duration 2.0 (0.13.0) months .
Safety .
Discussion .
This suggests that the EORTC QLQC30 questionnaire is sensitive ,  contrary to a previous  report .
